- Reimbursement Support
- Billing & Coding Information
- Forms & Resources
- Commercial Payors
- Medicare Coverage
Financial Assistance Programs
Xeomin Reimbursement Overview
Our reimbursement specialists can help you navigate the challenging healthcare environment by providing:
- General billing and coding information for XEOMIN
- For patients who have been determined appropriate for XEOMIN treatment by their physician, assistance with:
- Information regarding current coverage for XEOMIN.
Learn more about the reimbursement support for XEOMIN that Merz provides.
*Reimbursement staff can provide assistance with PA denials and Appeals for approved indications only and can help research the reason for denial in the case of unapproved uses.
Regional Reimbursement Team
For those patients who have been determined appropriate for XEOMIN treatment, Merz Pharmaceuticals also has an experienced, dedicated field reimbursement team that is able to assist you with support for XEOMIN through the ever changing healthcare landscape.
Important Billing & Coding Information
|HCPCS Codes||J0588 INJECTION, INCOBOTULINUMTOXIN A, 1 UNIT (effective January 1, 2012)*
Billed in product units, e.g., 50 or 100 Units
Click here to view additional information about these HCPCS codes.
|*Although other codes will become obsolete 12/31/2011, some commercial payors may continue to accept the product-specific Q-code (Q2040, Injection, incobotulinumtoxinA, 1 Unit), J3490, J3590 or C9278 after 1/1/2012. Providers should check with the payor prior to submitting a claim to confirm the preferred code.|
(The labeler codes in these NDCs are for Merz Pharmaceuticals, LLC.)
|0259-1605-01 (50 units/vial)
0259-1610-01 (100 units/vial)
Note: Some payors require 11 digit codes which are 00259-1605-01 and 00259-1610-01. In order to comply with these requirements to submit an 11 digit code, an additional 0 is added in front of the 10 digit NDC number.
Click here for additional billing and coding Information for XEOMIN
Please see the following sample forms for guidance when completing a Xeomin claim:
Information provided by Merz through reimbursement support is not a guarantee of insurance benefits or of payment. All benefits are subject to the insured's plan and verbal verifications provided by insurers are not a substitute for written policy information. Under no circumstances shall Merz be held responsible or liable for payment of any claims, benefits or cost. The practitioner must determine, based on independent medical judgment, to use XEOMIN for the specified treatment of his or her patient(s).